A clinical study examining the kallikrein-kinin system, which involves bradykinin, in septic cardiomyopathy has reached completed status as of July 28, 2026. The trial is registered as NCT06080282 and titled "Role of the Kallikrein-kinin System in Septic Cardiomyopathy."
No phase was specified for this study in the available record. The listing on ClinicalTrials.gov confirms the completed status but does not include reported results in this update. Bradykinin remains classified as an unapproved compound used in research settings, and this trial update does not change that status.
This brief reports only the status change and does not summarize any outcomes, since none were provided in the event data. Readers should not interpret trial completion as evidence of safety or effectiveness. Further details on the study design, endpoints, or any posted results would need to be confirmed directly through the official registry listing.
For additional context on bradykinin as a research compound, readers can consult the compound overview.